Beijing Surgerii Robotics Company Limited (Surgerii Robotics) recently closed a $100 million Series D financing led by Loyal Valley Capital. Company executives said the money will help the company advance and market its core product, the SHURUI Single-Port Surgical Robot both domestically and internationally, and accelerate the development of its next-generation products.

This financing round garnered strong backing from both new and existing investors, including Shanghai Healthcare Capital, a strategic investor in healthcare segment leaders; V Star Capital and DNV Capital, both specializing in innovative healthcare investments; and Hefei Industrial Investment, an investor with extensive experience and industrial resources in hard technology and strategic emerging industries. This diverse, robust shareholder base provides the company with sustained capital support for continuous innovation, enhanced strategic vision, and strong resource synergies.

The SHURUI SP Robot’s core technology is based on the “Dual Continuum Mechanism” design developed by Shanghai Jiao Tong University Professor Kai Xu. This design enabled the company to design the SHURUI SP Robot with snake-like surgical instruments that can perform highly complex and precise surgical procedures through a single minimal 1.8 cm incision.

During this financing round, investors conducted a systematic review of the company’s IP portfolio, thoroughly mapping the global technological and patent landscape in surgical robotics. This included a detailed comparative analysis between the SHURUI SP Robot and more than 3,000 valid, granted patents held by leading global endoscopic surgical robot companies across Europe and the United States. The analysis indicates that despite the highly dense patent landscape in this field, the SHURUI SP Robot has achieved disruptive innovation and breakthroughs in key technologies through its proprietary Dual Continuum Mechanism technology. This approach distinguishes itself significantly from the existing international surgical robotics patent framework, according to company executives.

The SHURUI SP Robot obtained the marketing approval from China’s National Medical Products Administration (NMPA) in June 2023, becoming the first approved single-port endoscopic surgical robot in China. In August 2025, it received CE certification, enabling its use in surgical procedures across urology, gynecology, general surgery, and thoracic surgery for both adult and pediatric patients. It is billed as the only single-port surgical robot with CE certification approved for pediatric use, and the first Chinese surgical robot to be certified for the use in patients of all age group.

To date, Surgerii Robotics has established clinical cooperation with over 70 Grade A tertiary hospitals in China, performed more than 3,000 surgeries, pioneered nearly 50 surgical procedures worldwide and developed over 80 surgical techniques that fill gaps in clinical practice across Asia or China. These procedures range from pancreaticoduodenectomy for pancreatic cancer to surgeries on pediatric patients as young as seven days old, demonstrating the strength of disruptive technology that achieves smaller surgical trauma while covering an even broader patient population than multi-port surgical robot.

Leveraging the support from this new financing round, the company will further the robot’s clinical adoption, develop advanced energy instruments, and create a systematic solution centered on cutting-edge technology to benefit a wider range of patients.

In 2025, Surgerii Robotics established the European Clinical Excellence Center in collaboration with IRCAD, an institution for minimally invasive surgical training. Leveraging its position as the only single-port surgical robot with CE certification for pediatric use, Surgerii Robotics has set its strategic focus on the high-end European market.

The completion of this financing round occurs as Surgerii Robotics deepens its domestic market penetration and accelerates international commercialization. The joint support and resource injection from new and existing investors further provide the company with ample capital and strategic confidence for accelerated implementation of its global strategy, enabling broader clinical adoption and large-scale deployment of the SHURUI SP Robot, expanding its global market and service network, accelerating the R&D of next-generation technologies, and delivering a new generation of minimally invasive surgical solutions to patients and medical professionals worldwide.